No­vo-part­nered mi­cro­cap biotech forced to halt PhI­II en­roll­ment in Rus­sia and Ukraine as war con­tin­ues

Rus­sia’s in­va­sion of Ukraine con­tin­ues to im­pact the bio­phar­ma in­dus­try, with a mi­cro­cap play­er an­nounc­ing Mon­day it will be forced to de­lay a piv­otal study read­out.

Though a blip in the grand scheme of things com­pared to the bomb­ing of res­i­den­tial ar­eas, ma­ter­ni­ty hos­pi­tals and nu­clear pow­er plants, Rus­sia’s war is prompt­ing No­vo Nordisk part­ner Aeter­na Zen­taris to halt Phase III en­roll­ment at Ukrain­ian and Russ­ian tri­al sites. Af­ter al­ready be­ing de­layed by the pan­dem­ic, the study will now like­ly push in­to 2023 as at least 25% of the ex­pect­ed pa­tients were slat­ed to come from Rus­sia and Ukraine, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER